260 related articles for article (PubMed ID: 37151412)
1. Tirzepatide and prevention of chronic kidney disease.
Bosch C; Carriazo S; Soler MJ; Ortiz A; Fernandez-Fernandez B
Clin Kidney J; 2023 May; 16(5):797-808. PubMed ID: 37151412
[TBL] [Abstract][Full Text] [Related]
2. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
[TBL] [Abstract][Full Text] [Related]
3. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
Min T; Bain SC
Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
[TBL] [Abstract][Full Text] [Related]
5. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
6. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
Wong E; Cope R; Dima L; Nguyen T
Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
[TBL] [Abstract][Full Text] [Related]
7. Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.
MacIsaac RJ; Deed G; D'Emden M; Ekinci EI; Hocking S; Sumithran P; Rasalam R
Diabetes Ther; 2023 Dec; 14(12):1997-2014. PubMed ID: 37824027
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.
Sinha R; Papamargaritis D; Sargeant JA; Davies MJ
J Obes Metab Syndr; 2023 Mar; 32(1):25-45. PubMed ID: 36750526
[TBL] [Abstract][Full Text] [Related]
9. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.
Cho YK; La Lee Y; Jung CH
J Lipid Atheroscler; 2023 Sep; 12(3):213-222. PubMed ID: 37800107
[TBL] [Abstract][Full Text] [Related]
10. Tirzepatide: A Systematic Update.
Forzano I; Varzideh F; Avvisato R; Jankauskas SS; Mone P; Santulli G
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498958
[TBL] [Abstract][Full Text] [Related]
11. Tirzepatide: Clinical review of the "twincretin" injectable.
Krauss Z; Hintz A; Fisk R
Am J Health Syst Pharm; 2023 Jul; 80(14):879-888. PubMed ID: 37070418
[TBL] [Abstract][Full Text] [Related]
12. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
[TBL] [Abstract][Full Text] [Related]
13. Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
Razzaki TS; Weiner A; Shukla AP
Ther Clin Risk Manag; 2022; 18():955-964. PubMed ID: 36199834
[TBL] [Abstract][Full Text] [Related]
14. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
Sardar MB; Nadeem ZA; Babar M
Curr Probl Cardiol; 2024 May; 49(5):102489. PubMed ID: 38417475
[TBL] [Abstract][Full Text] [Related]
15. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
16. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
18. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
Nicholls SJ; Tofé S; le Roux CW; D'Alessio DA; Wiese RJ; Pavo I; Brown K; Weerakkody GJ; Zeytinoglu M; Romera IC
Cardiovasc Diabetol; 2024 Feb; 23(1):63. PubMed ID: 38341541
[TBL] [Abstract][Full Text] [Related]
19. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.
Dutta P; Kumar Y; Babu AT; Giri Ravindran S; Salam A; Rai B; Baskar A; Dhawan A; Jomy M
Cureus; 2023 May; 15(5):e38379. PubMed ID: 37265914
[TBL] [Abstract][Full Text] [Related]
20. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
